Clinical trial · Interventional
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma
NCT03396952CI-TRIAL-00061429completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, ipilimumab, and aspirin may work better in treating patients with melanoma.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IIIA Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Stage IIIB Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Stage IIIC Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Stage III Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Stage IV Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Drug | Aspirin | ALIAS |
| Ipilimumab | Biological | Ipilimumab | ALIAS |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
| Pembrolizumab | Biological | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (pembrolizumab, ipilimumab, aspirin)
- description
- Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
- interventionNames
- Drug: Aspirin
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- Up to 12 weeks
- description
- Defined as the proportion of subjects for whom the best overall response at week 12 is confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST). Point estimates of ORR and 95% confidence intervals will be provided. Only participants with confirmed response are included in this analysis.
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Leukocytes \>= 3,000/microliter (mcL) * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Total bilirubin =\< 1.5 X institutional upper limit * Aspartate aminotransferase (AST) \[serum glutamic-oxaloacetic transaminase (SGOT)\] =\< 2.5 X institutional upper limit of normal * Alanine aminotransferase (ALT) \[serum glutamate pyruvate transaminase (SGPT)\] =\< 2.5 X institutional upper limit of normal * Creatinine =\< 1.5 X upper limit of normal (ULN) * Women of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Women of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject * Men of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject * Ability to understand a written informed consent document, and the willingness to sign it Exclusion Criteria: * Any mental or physical condition or disease or past medical history that mitigates against following the protocol * History of active autoimmune diseases such as but not limited to Crohn?s disease, ulcerative colitis, Sjogren's syndrome, requiring active immune suppression; patient may have hay fever or controlled asthma * Any solid organ transplant or bone marrow transplant * Any other disseminated malignancy. Exceptions include: localized prostate cancer, basal or squamous cell skin cancer, localized cervical cancer, and localized breast cancer. * Uncontrolled central nervous system (CNS) metastasis; patients with CNS metastasis can be eligible if definitively treated with radiotherapy or surgery * Any coexistent medical condition interfering with drug absorption * History of gastritis or malabsorption syndrome or aspirin intolerance or allergy * Live vaccination within the last 30 days * History of multiple sclerosis, type 1 diabetes mellitus (DM) or Guillain-Barre syndrome * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
References
Publications (0)
Data not yet available
No reference posted for this study.